Drug Resistance: from Bacteria to Cancer

Overview

Journal Mol Biomed

Specialties Biomedical Engineering
General Medicine
Pathology

Date 2022 Jan 10

PMID 35006446

Authors

Harsh Patel

Zhuo-Xun Wu

Yanglu Chen

Letao Bo

Zhe-Sheng Chen

Affiliations

Soon will be listed here.

Abstract

The phenomenon of drug resistance has been a hindrance to therapeutic medicine since the late 1940s. There is a plethora of factors and mechanisms contributing to progression of drug resistance. From prokaryotes to complex cancers, drug resistance is a prevailing issue in clinical medicine. Although there are numerous factors causing and influencing the phenomenon of drug resistance, cellular transporters contribute to a noticeable majority. Efflux transporters form a huge family of proteins and are found in a vast number of species spanning from prokaryotes to complex organisms such as humans. During the last couple of decades, various approaches in analyses of biochemistry and pharmacology of transporters have led us to understand much more about drug resistance. In this review, we have discussed the structure, function, potential causes, and mechanisms of multidrug resistance in bacteria as well as cancers.

Citing Articles

The impact of the ATP-binding cassette (ABC) transporter family on multidrug resistance in head and neck tumors.

Zhang W, Zhu Z, Liu Y Mol Biol Rep. 2025; 52(1):256.

PMID: 39982595 DOI: 10.1007/s11033-025-10321-9.

FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells.

Zhang M, Zeng X, She M, Dong X, Chen J, Xiong Q Braz J Med Biol Res. 2024; 57:e13357.

PMID: 38958364 PMC: 11221864. DOI: 10.1590/1414-431X2024e13357.

Nanotechnology-based delivery systems to overcome drug resistance in cancer.

Patel H, Li J, Bo L, Mehta R, Ashby Jr C, Wang S Med Rev (2021). 2024; 4(1):5-30.

PMID: 38515777 PMC: 10954245. DOI: 10.1515/mr-2023-0058.

USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy.

Young M, Wang S, Chen Y, Liu C, Hsu K, Tang S Cell Death Differ. 2024; 31(5):574-591.

PMID: 38491202 PMC: 11093971. DOI: 10.1038/s41418-024-01277-7.

IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells.

Kong X, Cheng D, Xu X, Zhang Y, Li X, Pan W Mol Med Rep. 2024; 29(5).

PMID: 38488034 PMC: 10975025. DOI: 10.3892/mmr.2024.13200.

References

Kashiwayama Y, Seki M, Yasui A, Murasaki Y, Morita M, Yamashita Y . 70-kDa peroxisomal membrane protein related protein (P70R/ABCD4) localizes to endoplasmic reticulum not peroxisomes, and NH2-terminal hydrophobic property determines the subcellular localization of ABC subfamily D proteins. Exp Cell Res. 2008; 315(2):190-205. DOI: 10.1016/j.yexcr.2008.10.031. View

Calvisi D, Pascale R, Feo F . Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials. 2008; 2(3):217-36. DOI: 10.2174/157488707781662715. View

Marchetti S, de Vries N, Buckle T, Bolijn M, van Eijndhoven M, Beijnen J . Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008; 7(8):2280-7. DOI: 10.1158/1535-7163.MCT-07-2250. View

Young L, Campling B, Cole S, Deeley R, Gerlach J . Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001; 7(6):1798-804. View

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L . P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2016; 3:54-66. PMC: 4739423. DOI: 10.1016/j.ebiom.2015.12.009. View

Marin J, Briz O, Monte M, Blazquez A, Macias R . Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets. 2012; 12(4):402-38. DOI: 10.2174/156800912800190875. View

Leschziner G, Zabaneh D, Pirmohamed M, Owen A, Rogers J, Coffey A . Exon sequencing and high resolution haplotype analysis of ABC transporter genes implicated in drug resistance. Pharmacogenet Genomics. 2006; 16(6):439-50. DOI: 10.1097/01.fpc.0000197467.21964.67. View

Riechelmann R, Tannock I, Wang L, Saad E, Taback N, Krzyzanowska M . Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007; 99(8):592-600. DOI: 10.1093/jnci/djk130. View

Paulsen I, Skurray R, Tam R, Saier Jr M, Turner R, Weiner J . The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol Microbiol. 1996; 19(6):1167-75. DOI: 10.1111/j.1365-2958.1996.tb02462.x. View

10.

Dean M, Rzhetsky A, Allikmets R . The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11(7):1156-66. DOI: 10.1101/gr.184901. View

11.

Bolhuis H, Poelarends G, van Veen H, Poolman B, Driessen A, Konings W . The Lactococcal lmrP gene encodes a proton motive force-dependent drug transporter. J Biol Chem. 1995; 270(44):26092-8. DOI: 10.1074/jbc.270.44.26092. View

12.

Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A . Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004; 64(4):1403-10. DOI: 10.1158/0008-5472.can-3263-2. View

13.

Kool M, de Haas M, Scheffer G, Scheper R, Van Eijk M, Juijn J . Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997; 57(16):3537-47. View

14.

Saier Jr M, Paulsen I . Phylogeny of multidrug transporters. Semin Cell Dev Biol. 2001; 12(3):205-13. DOI: 10.1006/scdb.2000.0246. View

15.

Rocchi E, Khodjakov A, Volk E, Yang C, Litman T, Bates S . The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 2000; 271(1):42-6. DOI: 10.1006/bbrc.2000.2590. View

16.

Bakos E, Evers R, Szakacs G, Tusnady G, Welker E, Szabo K . Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem. 1998; 273(48):32167-75. DOI: 10.1074/jbc.273.48.32167. View

17.

Wu C, Calcagno A, Hladky S, Ambudkar S, Barrand M . Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 2005; 272(18):4725-40. PMC: 1350838. DOI: 10.1111/j.1742-4658.2005.04888.x. View

18.

Jedlitschky G, Hoffmann U, Kroemer H . Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol. 2006; 2(3):351-66. DOI: 10.1517/17425255.2.3.351. View

19.

Lambert G, Estevez-Salmeron L, Oh S, Liao D, Emerson B, Tlsty T . An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer. 2011; 11(5):375-82. PMC: 3488437. DOI: 10.1038/nrc3039. View

20.

Cole S, Bhardwaj G, Gerlach J, MACKIE J, Grant C, Almquist K . Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992; 258(5088):1650-4. DOI: 10.1126/science.1360704. View